Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Pre-Mkt 06-04 08:21:28 EDT

1.01

-0.03

-2.88%

盘前1.03

+0.02+1.98%

08:20 EDT

High1.04	Low1.00	Vol97.71K
Open1.04	D1 Closing1.04	Amplitude3.85%
Mkt Cap42.29M	Tradable Cap35.29M	Total Shares41.88M
T/O99.53K	T/O Rate0.28%	Tradable Shares34.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.01,"timestamp":1780516800000,"preClose":1.04,"halted":0,"volume":97714,"hourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":1.01,"latestTime":"08:20 EDT","volume":14941,"amount":15424.620746699999,"timestamp":1780575637209,"change":0.02,"changeRate":0.019802,"amplitude":0.064356},"delay":0,"changeRate":-0.028846153846153872,"floatShares":34944200,"shares":41876087,"eps":-1.4419,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"06-04 08:21:28 EDT","open":1.04,"high":1.04,"low":1,"amount":99531.3631432,"amplitude":0.038462,"askPrice":1.05,"askSize":50,"bidPrice":1,"bidSize":130,"shortable":3,"etf":0,"ttmEps":-1.4419,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780579800000},"marketStatusCode":1,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.01,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":1.01,"latestTime":"08:20 EDT","volume":14941,"amount":15424.620746699999,"timestamp":1780575637209,"change":0.02,"changeRate":0.019802,"amplitude":0.064356},"postHourTrading":{"tag":"盘后","latestPrice":0.9898,"preClose":1.01,"latestTime":"19:55 EDT","volume":12971,"amount":12962.3647,"timestamp":1780530954147,"change":-0.0202,"changeRate":-0.02,"amplitude":0.069505},"volumeRatio":0.3852559197957467},"requestUrl":"/m/hq/s/MIRA","defaultTab":"news","newsList":[{"id":"2640521021","title":"Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2640521021","media":"Reuters","labels":["corporation","event"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2640521021?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574430,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals executed an amended exclusive license with MIRALOGX, securing worldwide exclusive rights to MIRA-55 and SKNY-1.Deal grants global development, commercialization, sublicensing, IP enforcement rights for both assets, tightening control of the company’s pipeline.MIRA-55 is an oral investigational candidate for chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders.Amendment leaves previously disclosed core economic terms of existing license arrangements largely unchanged.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL793X6h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015227","title":"Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640015227?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:03","pubTimestamp":1780574582,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0M8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688567","title":"MIRA Expands Global Ketamir-2 License for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688567?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:37","pubTimestamp":1779885424,"startTime":"0","endTime":"0","summary":"An announcement from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. On May 21, 2026, MIRA Pharmaceuticals amended its exclusive Ketamir-2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507708","title":"Mira Pharmaceuticals Inc: Entered Into Amendment No 1 to Exclusive License Agreement With Miralogx Llc - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507708?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507050","title":"Mira Pharmaceuticals Inc - Expands Ketamir-2 Patent Portfolio to 10 Major Markets - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507050?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883731,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240K6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507439","title":"Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507439","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507439?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:01","pubTimestamp":1779883291,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals expanded its exclusive Ketamir-2 license to worldwide rights under an amended agreement with MIRALOGX.Broader IP coverage spans 10 major markets, supporting global partnering options as Ketamir-2 advances toward Phase 2a in CIPN.The amendment leaves the previously disclosed core economic terms of the original license agreement largely unchanged.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8dsWB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549778","title":"Mira Pharmaceuticals management to meet with Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549778?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:54","pubTimestamp":1779814484,"startTime":"0","endTime":"0","summary":"Meeting to be held on May 27 hosted by Maxim. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635639740","title":"Mira Pharmaceuticals Q1 net loss narrows to $1.15 million; revenue flat at no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635639740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635639740?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:04","pubTimestamp":1778785473,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals posted a net loss of $1.15 million, narrowing from $1.78 million a year earlier, while loss per share improved to $0.03 from $0.11.Operating costs fell to $1.1 million from $1.81 million, as general and administrative expense dropped to $578,698 from $1.49 million.Research and development spending climbed to $524,781 from $314,404.Cash declined to $4.82 million from $6.35 million at Dec. 31, while short-term investments edged down to $4.59 million from $4.68 million.Ketamir-2 completed Phase 1 dosing and is being advanced toward a Phase 2a CIPN study in first half 2026, while MIRA-55 and SKNY-1 remained in preclinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL7wKZ09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759662","title":"MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759662","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759662?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:14","pubTimestamp":1778706865,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has issued an update. MIRA Pharmaceuticals, Inc. reported positive unblinded results from a completed Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-ketamir-2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-ketamir-2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635275345","title":"Mira Pharmaceuticals publishes investor presentation on Ketamir-2 for chemotherapy-induced peripheral neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635275345","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635275345?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:20","pubTimestamp":1778703609,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals highlighted Ketamir-2, an oral selective NMDA receptor modulator being developed for chemotherapy-induced peripheral neuropathy, a condition it estimates affects 30%-40% of chemotherapy patients with no FDA-approved treatments.Phase 1 program completed in 56 healthy volunteers with 0 serious adverse events, testing doses up to 600 mg.Phase 2a protocol submission targeted for H1 2026 under an active IND, with enrollment expected to begin in 2026 and first readout expected in Q1 2027.Planned Phase 2a design calls for a randomized, double-blind, placebo-controlled, three-period crossover study in 24 patients, evaluating 150 mg and 300 mg oral doses.Estimated all-in cost for Phase 2a cited at USD 4-6 million, with management describing the company as debt-free.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4VqDyM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758990","title":"Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758990","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758990?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:04","pubTimestamp":1778702687,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals reported positive unblinded results from its completed Phase 1 trial of oral Ketamir-2; no future presentation was disclosed.Study met key early-stage objectives, with results supporting a favorable safety and tolerability profile in healthy volunteers.Data also indicated drug exposure consistent with potential once-daily dosing, subject to further clinical testing.Company is preparing to submit Phase 2a materials to FDA to start a mid-stage study in chemotherapy-induced peripheral neuropathy under its active IND.DEA review concluded Ketamir-2 is not classified as a controlled substance, removing a potential regulatory constraint ahead of later-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbZfH5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943731","title":"Mira announces acceptance of peer-reviewed SKNY-1 manuscript","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635943731?lang=en_us&edition=fundamental","pubTime":"2026-05-14 00:28","pubTimestamp":1778689697,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (MIRA) announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and acti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-announces-acceptance-of-peer-reviewed-skny-1-manuscript-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-announces-acceptance-of-peer-reviewed-skny-1-manuscript-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635843227","title":"MIRA highlights SKNY-1 preclinical data in new publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2635843227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635843227?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673639,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) just unveiled an announcement. On May 13, 2026, MIRA Pharmaceuticals announced that a peer-reviewed manuscri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030789","title":"Mira Pharmaceuticals reports peer-reviewed preclinical study on obesity candidate SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030789?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:32","pubTimestamp":1778671973,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals on May 13, 2026 announced publication of peer-reviewed preclinical research on oral candidate SKNY-1, with results already presented in the journal article.Study reported SKNY-1 produced weight loss in an obesity-model zebrafish study without signs of harmful loss of body mass quality over the short treatment period.Researchers also described improvements in lipid-related measures, lower fat buildup in liver tissue, supported by shifts in appetite-related gene activity.Behavior tests showed reduced compulsive feeding and nicotine-seeking signals, supporting development rationale in obesity and nicotine addiction.Update did not disclose any new or upcoming human clinical trial timelines, leaving near-term value inflection tied to additional preclinical work or future clinical initiation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL39L1r1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625600813","title":"Mira Pharmaceuticals investor presentation highlights Ketamir-2 advancing to Phase 2a neuropathic pain trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625600813","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625600813?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:17","pubTimestamp":1775517431,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals outlined strategy to advance oral drug pipeline targeting neurologic, neuropsychiatric, metabolic disorders.Lead asset Ketamir-2, oral ketamine analog, completed Phase 1 with favorable safety and tolerability.Program slated to move into Phase 2a study in chemotherapy-induced peripheral neuropathy.Presentation states DEA review found Ketamir-2 is not a controlled substance, positioning it as a non-opioid option for neuropathic pain.Pipeline also features SKNY-1 for obesity and smoking cessation, MIRA-55 for anxiety reduction and cognition support in aging.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief on April 06, 2026, and is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL31cxSs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555998","title":"Mira Pharmaceuticals FY25 net loss widens to $10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555998","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555998?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:36","pubTimestamp":1774996574,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals posted a net loss of USD 10 million for fiscal 2025.Total operating costs climbed to USD 10 million, driven by higher general and administrative expense.Cash and cash equivalents rose to USD 6 million at Dec. 31, 2025.Mira completed dosing in a Phase 1 trial of Ketamir-2 in healthy volunteers, targeting a Phase 2a study in chemotherapy-induced peripheral neuropathy in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbM3gb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621314098","title":"What's Going On With MIRA Pharma Stock Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621314098","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621314098?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:22","pubTimestamp":1774358520,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (NASDAQ: MIRA) eyes IND submission for Mira-55 after new 2026 data confirms no CNS side effects.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/24/Market-Volatility-Ahead.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/24/Market-Volatility-Ahead.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51430640/whats-going-on-with-mira-pharma-stock-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51430640/whats-going-on-with-mira-pharma-stock-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MIRA","IND","BK4007","CNS","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706953","title":"Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706953","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706953?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:00","pubTimestamp":1774270822,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals reported new preclinical behavioral assay results for Mira-55 showing no THC-like central nervous system side effects at oral doses of 10, 30, and 100 mg/kg.The results have already been presented in the announcement and were based on hypothermia, catalepsy, Elevated Plus Maze, and Open Field tests comparing Mira-55 with THC and rimonabant.Across the assays, Mira-55 showed no evidence of sedation, catalepsy, motor impairment, or anxiogenic effects, while rimonabant showed anxiety-like behavioral changes in the Open Field test.The company said the findings support plans to advance Mira-55 toward an investigational new drug submission for inflammatory pain.Market analysis cited in the announcement estimated the global non-opioid pain treatment market at USD 45.3 billion in 2024 and projected USD 70.3 billion by 2030.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLb4kZf4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620809265","title":"Visionstate Builds Recurring Revenue as MIRA Platform Wins New Subscriptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2620809265","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620809265?lang=en_us&edition=fundamental","pubTime":"2026-03-19 01:08","pubTimestamp":1773853705,"startTime":"0","endTime":"0","summary":"The latest update is out from Visionstate ( ($TSE:VIS) ). Visionstate reported accelerating growth in subscriptions to its MIRA compliance platform...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/visionstate-builds-recurring-revenue-as-mira-platform-wins-new-subscriptions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/visionstate-builds-recurring-revenue-as-mira-platform-wins-new-subscriptions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616837277","title":"MIRA Completes Phase 1 Trial of Ketamir-2 Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2616837277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616837277?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:44","pubTimestamp":1772574242,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. MIRA Pharmaceuticals, Inc. announced it has completed dosing in a Phase 1 clinical t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-completes-phase-1-trial-of-ketamir-2-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-completes-phase-1-trial-of-ketamir-2-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":-0.1255},{"period":"1month","weight":-0.0194},{"period":"3month","weight":-0.1441},{"period":"6month","weight":-0.3082},{"period":"1year","weight":-0.2681},{"period":"ytd","weight":-0.3311}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0505},{"period":"3month","weight":0.107},{"period":"6month","weight":0.1},{"period":"1year","weight":0.2653},{"period":"ytd","weight":0.1061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}